KRAS and melanoma: We also observed that the KRAS mutation status showed no connection with Ras dependency, suggesting that Ras dependency may be a unique feature that might allow us to assess a patient’s prognosis for drug resistance in the clinical setting beyond the conventional scenarios in which Ras gene involvement might be considered a priority (e.g., pancreas, colon and lung tumors for KRAS and possibly melanoma for NRAS).